THE TAPE

CVS HEALTH CORPORATION

$88.59▼ −0.85%
Last close
Relative strength
40RS
of 99, against every stock▼ -16 on the month
Falling back
Caution
−7.9%
six months against the S&P 500
52-week range
−20.0%
from the high
$69.51$110.68
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +5% on a year ago
Why it is on no screen

CVS is off the screens on one check: relative strength.

A base has formed16.6 weeks, from 77.33 to 110.68.
Long enough to count16.6 weeks against 3 needed.
Shallow enough30.1% deep against 35% allowed.
Close to its pivot-20.0% from the pivot; listed down to -20%.
Relative strengthRS 40 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$84.84
-4.2% · tested 3× · last 26 sessions ago
Resistance above
$89.79
+1.4% · tested 3× · last 28 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

CVS HEALTH CORPORATION is not on any of the screens right now. Its relative strength rating is 40, and it sits in Retail-Drug Stores & Proprietary Stores.

Against its industry
CautionBehind its industry over all three, in an industry that is not ahead of the S&P 500.
One month against the S&P 500
-1.1%
Three months against the S&P 500
-3.2%
Six months against the S&P 500
-7.9%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same industry
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 7.2% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$420.6B
+5.4% year on year
Operating margin
3.6%
Net margin
2.6%
Free cash flow
$15.6B
13.7% of market cap
Price to sales
0.27×
Price to earnings
10.3×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$108.4B
+2.2% QoQ · +5.4% YoY
Gross margin
—
Net income
$2.2B
Positive
Free cash flow
$3.9B
Cash generating

What the numbers say

  • Revenue +5.4% year over year, +2.2% on the quarter
  • Good: Profitable: net income $2.17B, operating margin 3.3%
  • Good: Cash generating: operating cash flow $4.72B, free cash flow $3.91B
  • Net debt $45.48B · cash $11.74B
Revenue by quarter
Free cash flow
Net income
shares +1.7% in a year · net debt $45.5B

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 4 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new, 1 added, 2 trimmed, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-11
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Large insider purchaseFiling · 2026-11-07
Shah Prem S $2,001,315
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 55 nights). Against their own sector they have lagged by 1.0%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-05
below 20d & 50d on 3.8x volume at 79.96
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-05
-12.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-05
-12.5% on earnings 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Unusual volumeTape · 2026-11-05
7.4 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
A new options position openedOPTIONS · 2026-11-04
2026-11-20 80P: OI +3,984 on 4,019 volume, ~$0.4M in puts (+1 more strike)
Too few cases to judge yet (180 cases over 9 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-04
above 20d & 50d on 2.3x volume at 91.41
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
1
$2,001,315 total
Sold on the open market
1
$34,619,007 total

Bought: Shah Prem S. Sold: ROBBINS LARRY.

Not counted above: 4 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-06 Shah Prem S · EVP and Group Presidentbuy23,855$2,001,315
2026-06-26 Clark James David · SVP, Cont & Chief Acct Officerwithheld for tax454$41,305
2026-05-31 Newman Brian · EVP, Chief Financial Officerwithheld for tax2,478$225,448
2026-05-31 Compton-Phillips Amy · EVP, Chief Medical Officerwithheld for tax7,618$693,086
2026-05-21 AGUIRRE FERNANDO · Directordisposition to issuer1,563$146,142
2026-05-21 ROBBINS LARRY · Directorsell370,462$34,619,007

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy7
Buy18
Hold3
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
CVS HEALTH CORPORATION (CVS) — The Tape